Clinical Trial: Cancer, Lung Cancer

BMSCA209-817:A Phase Illb/IV Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer

Full Name

BMSCA209-817: A Phase Illb/IV Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer

Description

Experimental: Nivolumab in combination with Ipilimumab

Intervention: Drug: Nivolumab in combination with Ipilimumab

Eligibility

Inclusion Criteria
Inclusion Criteria: Histologically confirmed Stage 4 or recurrent non-small cell lung cancer Eastern Cooperative Oncology Group (ECOG) score 0-1 (Physically able to carry out light housework or office work through to being fully active as you were before cancer) No prior systemic anticancer therapy (including EGFR and ALK inhibitors) Tissue or Programmed death-ligand 1 (PD-L1) results available

Exc

Exclusion Criteria
Exclusion Criteria: Untreated brain metastases An active malignancy that requires concurrent intervention Active, known or suspected autoimmune disease Carcinomatous meningitis, which means there is inflammation of the covering of the brain, caused by cancer

Other protocol defined inclusion/exclusion criteria could apply

Doctor(s) Running This Study